Lifeboat Foundation

New research exploring theories of aging has found that small mutations accumulating in DNA are unlikely to be fully responsible for this process.

The research, a collaboration between the Wellcome Sanger Institute, University of Birmingham, University of Edinburgh and others, found that human cells and tissues can accumulate many more mutations than are normally present, without the body showing the features associated with aging.

The new study, published today (30 September) in Nature Genetics, compared DNA taken from individuals with inherited mutations in genes involved in DNA replication with DNA from individuals who have normal versions of these genes. The researchers aimed to understand the impact of defective DNA replication on cancer risk and features associated with aging. The results suggest that build-up of mutations in normal cells is unlikely to be the only factor in the development of age-related disease, adding to the ongoing debate about the causes of aging.

Artificial sweeteners are widely promoted as safe, zero-calorie alternatives to sugar, ideal for those trying to lose weight. But a new study is indicating artificial sweeteners may increase appetite and food cravings, particularly in females and the obese.

“There is controversy surrounding the use of artificial sweeteners because a lot of people are using them for weight loss,” says corresponding author on the new study, Kathleen Page. “While some studies suggest they may be helpful, others show they may be contributing to weight gain, type 2 diabetes and other metabolic disorders. Our study looked at different population groups to tease out some of the reasons behind those conflicting results.”

Page hypothesizes the discordancy in the science is somewhat due to the fact that many studies investigating the effects of artificial sweeteners on metabolic activity or the brain are conducted in mostly male subjects, often with normal weight. This new research set out to investigate the influence of artificial sweeteners on these processes across a broad cohort of men and women.

Genetic diseases are a compelling target for viral gene therapy. One condition that scientists are investigating to see if they can treat with gene therapy is a rare genetic disease called Leber congenital amaurosis, or LCA is a progressive condition that disables critical cells within the retina. The damage begins at birth: it eventually robs patients of central vision and color perception, often rendering them legally blind. But there may be another way. On Wednesday, researchers presented evidence from a breakthrough gene-editing experiment that restored some color vision to patients with LCA vision loss.

CRISPR is already under investigation as a gene therapy for blood disorders like sickle cell disease and beta-thalassemia. It may well have other uses, such as treating cancer by editing mutated DNA. But the process is not without its hurdles. Treatments for blood disorders like these involve taking cells from the patient’s body, changing them in vitro in the lab, and then re-infusing them back into the patient’s body. That works great for blood, which you can take out, filter, and put back in with relatively few consequences.

But because LCA is a disease of the retina, you can’t just take out cells and then infuse them back in. The retina is a delicate, multilayered membrane that resents any disturbance. The eye also has a system of physical defenses not unlike the blood-brain barrier. Furthermore, the immune system sometimes responds with extreme prejudice to eye injuries or infections, to the point of causing an actual autoimmune disease where the body attacks its own eyes. How, then, could researchers get the CRISPR treatment into the retina, past the body’s ferocious defenses and without further damage?

(https://www.linkedin.com/in/evelyne-yehudit-bischof/) is an expert in internal medicine and oncology, with a focus on preventative and precision medicine, bio-gerontology, and geronto-oncology.

Dr. Bischof is deeply passionate about next-generation medical technology, and the applications of artificial intelligence for biomedical research and practice.

Continue reading “Dr. Evelyne Bischof, MD — Advancing The Frontiers Of Preventative And Precision Longevity Medicine” »

Fixing breaks in genes with speed and perfection can be a matter of life and death for most organisms. Even the simplest changes in a sequence risk catastrophe, especially if the altered code is responsible for a critical function.

Over the past half a century, biologists have studied the mechanisms involved to piece together most of the major steps involved in making faithful repairs in DNA. Yet, one part of the process has remained frustratingly unclear.

By marking key enzymes and DNA with fluorescent tags and watching the repair process unfold in real-time in an Escherichia coli model, researchers from Uppsala University in Sweden have filled in missing details on how bacteria find the templates they rely on to keep genetic repairs error-free.

New #preprint from JAX’s Nadia Rosenthal and researchers at Rocky Mountain Laboratories: “Genetically diverse mouse models of SARS-CoV-2 infection recapitulate clinical variation and cytokine responses in COVID-19”

The preprint, which has yet to be peer reviewed, shows that mice with different genetic backgrounds exhibit highly variable responses to SARS-CoV-2 infection, mirroring the large differences in #COVID19 disease severity seen in humans:

Since the advent of the COVID-19 pandemic, tremendous progress has been made in developing effective vaccines against SARS-CoV-2, the coronavirus that causes COVID-19, and in treating ill patients. Nonetheless, much more needs to be learned about SARS-CoV-2 infectivity and COVID-19 progression to lessen the continuing threat of infection, as the recent emergence and rapid spread of the delta variant has emphasized.

Among thousands of the earliest survivors of COVID-19 in Wuhan, China, nearly half had at least one persistent symptom a full year after being released from the hospital, according to a new study published in JAMA Network Open.

The study followed up with 2,433 adult patients who had been hospitalized in one of two hospitals in Wuhan early on in the pandemic. Most had nonsevere cases, but a small number had severe COVID-19 and required intensive care. All of the patients were discharged between February 12 and April 10 2020, and the study follow-up took place in March of 2021.

Overall, 45 percent of the patients reported at least one symptom in that one-year follow-up. The most common symptoms were fatigue, sweating, chest tightness, anxiety, and myalgia (muscle pain). Having a severe case of COVID-19 increased the likelihood of long-lingering symptoms; 54 percent of the 680 severe cases reported at least one symptom after a year. But persistent symptoms were also common among the nonsevere cases, with 41.5 percent of 1,752 nonsevere cases reporting at least one symptom a year later.

Accounting and consulting firm PwC told Reuters on Thursday it will allow all its 40,000 U.S. client services employees to work virtually and live anywhere they want in perpetuity, making it one of the biggest employers to embrace permanent remote work.

The policy is a departure from the accounting industry’s rigid attitudes, known for encouraging people to put in late nights at the office. Other major accounting firms, such as Deloitte and KPMG, have also been giving employees more choice to work remotely in the face of the COVID-19 pandemic.

$100 million a year. All you gotta do is apply for funding.

A consortium of biotech founders, clinicians, and leading longevity research institutions announced today the launch of the Longevity Science Foundation. The new Swiss foundation has committed to distributing more than $1 billion over the next ten years to research, institutions and projects advancing healthy human longevity and extending the healthy human lifespan to more than 120 years.

Longevity. Technology: The Foundation is advised by a aptly-named “Visionary Board” of leading longevity researchers, led by Evelyne Bischof and joined by Andrea B Maier, Eric Verdin, Matt Kaeberlein and Alex Zhavoronkov, all key opinion leaders who be top picks for a longevity dream team.

Continue reading “$1B longevity fund launches to pursue 120+ lifespan” »